RS57253B2 - Selektivni modulatori fingozin 1-fosfat receptora i postupci asimetrične sinteze - Google Patents

Selektivni modulatori fingozin 1-fosfat receptora i postupci asimetrične sinteze

Info

Publication number: RS57253B2
Authority: RS; Serbia
Prior art keywords: methods; receptor modulators; phosphate receptor; chiral synthesis; selective sphingosine
Prior art date: 2009-11-13

Application number

RS20180647A

Other languages

English (en)

Inventor

Esther Martinborough

Marcus F Boehm

Adam Richard Yeager

Junko Tamiya

Liming Huang

Enugurthi Brahmachary

Manisha Moorjani

Gregg Alan Timony

Jennifer L Brooks

Robert Peach

Fiona Lorraine Scott

Michael Allen Hanson

Original Assignee

Receptos Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-13

Filing date

2010-11-15

Publication date

2024-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43992106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS57253(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-15 Application filed by Receptos Llc filed Critical Receptos Llc

2018-08-31 Publication of RS57253B1 publication Critical patent/RS57253B1/sr

2024-10-31 Publication of RS57253B2 publication Critical patent/RS57253B2/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

RS20180647A 2009-11-13 2010-11-15 Selektivni modulatori fingozin 1-fosfat receptora i postupci asimetrične sinteze RS57253B2 (sr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US26130109P	2009-11-13	2009-11-13
US26247409P	2009-11-18	2009-11-18
EP10830880.0A EP2498610B2 (en)	2009-11-13	2010-11-15	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PCT/US2010/056760 WO2011060392A1 (en)	2009-11-13	2010-11-15	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Publications (2)

Publication Number	Publication Date
RS57253B1 RS57253B1 (sr)	2018-08-31
RS57253B2 true RS57253B2 (sr)	2024-10-31

Family

ID=43992106

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20210360A RS61829B1 (sr)	2009-11-13	2010-11-15	Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
RS20180647A RS57253B2 (sr)	2009-11-13	2010-11-15	Selektivni modulatori fingozin 1-fosfat receptora i postupci asimetrične sinteze

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
RS20210360A RS61829B1 (sr)	2009-11-13	2010-11-15	Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze

Country Status (33)

Country	Link
US (4)	US8362048B2 (sr)
EP (3)	EP2498610B2 (sr)
JP (3)	JP5650233B2 (sr)
KR (2)	KR101752124B1 (sr)
CN (2)	CN102762100B (sr)
AU (1)	AU2010319983B2 (sr)
BR (2)	BR122018077504B8 (sr)
CA (2)	CA2986521C (sr)
CY (3)	CY1120338T1 (sr)
DK (2)	DK2498610T4 (sr)
EA (2)	EA035768B1 (sr)
ES (2)	ES2858337T3 (sr)
FI (1)	FI2498610T4 (sr)
FR (1)	FR20C1059I2 (sr)
HK (2)	HK1175948A1 (sr)
HR (2)	HRP20180874T4 (sr)
HU (3)	HUE054000T2 (sr)
IL (2)	IL219691B (sr)
LT (3)	LT2498610T (sr)
LU (1)	LUC00184I2 (sr)
MX (1)	MX2012005560A (sr)
MY (2)	MY161854A (sr)
NO (2)	NO2498610T3 (sr)
NZ (1)	NZ599915A (sr)
PH (2)	PH12012500939A1 (sr)
PL (2)	PL3406142T3 (sr)
PT (2)	PT3406142T (sr)
RS (2)	RS61829B1 (sr)
SG (1)	SG10201407357PA (sr)
SI (2)	SI2498610T2 (sr)
SM (2)	SMT201800288T1 (sr)
TR (1)	TR201807912T4 (sr)
WO (1)	WO2011060392A1 (sr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY160907A (en) *	2009-11-13	2017-03-31	Receptos Inc	Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PH12012500939A1 (en)	2009-11-13	2016-06-15	Receptos Llc	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2706999B1 (en)	2011-05-13	2019-08-28	Celgene International II Sàrl	Selective heterocyclic sphingosine 1 phosphate receptor modulators
MY169073A (en) *	2012-06-21	2019-02-13	Eisai R&D Man Co Ltd	Indanesulfamide derivative
WO2014158302A1 (en) *	2013-03-25	2014-10-02	Swenson Rolf Eric	Novel sphingosine 1-phosphate receptor antagonists
US20170165236A1 (en) *	2013-11-01	2017-06-15	Celgene International Ii Sàrl	Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
WO2016164180A1 (en)	2015-04-06	2016-10-13	Auspex Pharmaceuticals, Inc.	Deuterium-substituted oxadiazoles
CN109219597A (zh) *	2016-06-14	2019-01-15	苏州科睿思制药有限公司	奥扎莫德的晶型、其盐酸盐的晶型及其制备方法
CA3034796A1 (en)	2016-07-22	2018-01-25	Shijiazhuang Sagacity New Drug Development Co., Ltd.	S1p1 agonist and application thereof
CN109563059A (zh) *	2016-08-19	2019-04-02	苏州科睿思制药有限公司	奥扎莫德的晶型及其制备方法
WO2018049632A1 (zh) *	2016-09-14	2018-03-22	杭州领业医药科技有限公司	奥扎莫德的晶型、其制备方法及药物组合物
WO2018050091A1 (zh)	2016-09-14	2018-03-22	苏州科睿思制药有限公司	奥扎莫德盐酸盐的晶型及其制备方法
CA3038106A1 (en) *	2016-09-29	2018-04-05	Celgene International Ii Sarl	Compounds and methods for treating lupus
US10981900B2 (en) *	2017-02-28	2021-04-20	Medshine Discovery Inc.	Spiro compound and use thereof
WO2018184185A1 (zh) *	2017-04-07	2018-10-11	杭州领业医药科技有限公司	奥扎莫德加成盐晶型、制备方法及药物组合物和用途
CN108727291A (zh) *	2017-04-21	2018-11-02	宁波爱诺医药科技有限公司	奥扎莫德及其中间体的制备方法
CN108727292A (zh) *	2017-04-21	2018-11-02	宁波爱诺医药科技有限公司	一种奥扎莫德及其中间体的制备方法
EP3621610A1 (en)	2017-05-08	2020-03-18	Celgene International II Sàrl	Sphingosine 1 phosphate receptor agonists for neuroprotection
WO2018215807A1 (en) *	2017-05-22	2018-11-29	Egis Gyógyszergyár Zrt.	Process for the production of ozanimod
US10660879B2 (en)	2017-06-23	2020-05-26	Enzo Biochem, Inc.	Sphingosine pathway modulating compounds for the treatment of cancers
EP3641743A2 (en)	2017-06-23	2020-04-29	Enzo Biochem, Inc.	Sphingosine pathway modulating compounds for the treatment of cancers
CN109280035B (zh) *	2017-07-19	2023-06-09	广东东阳光药业有限公司	奥扎莫德的多晶型及其制备方法
CN110944982A (zh) *	2017-08-31	2020-03-31	苏州科睿思制药有限公司	奥扎莫德盐酸盐的晶型及其制备方法
WO2019058290A1 (en) *	2017-09-20	2019-03-28	Suven Life Sciences Limited	IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
WO2019094409A1 (en)	2017-11-07	2019-05-16	Teva Pharmaceuticals International Gmbh	Salts and solid state forms of ozanimod
CN107857760A (zh) *	2017-11-21	2018-03-30	南京天翔医药科技有限公司	鞘氨醇‑1‑磷酸受体调节剂及其应用
JP2021511375A (ja)	2018-01-18	2021-05-06	シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド	三環式化合物の結晶形、塩形及びその製造方法
CA3092295A1 (en)	2018-03-20	2019-09-26	Eisai R&D Management Co., Ltd.	Epilepsy treatment agent
CN110615747A (zh) *	2018-06-20	2019-12-27	广东东阳光药业有限公司	一种二氢茚中间体的制备方法
CA3124986A1 (en)	2018-06-25	2020-01-02	Enzo Biochem, Inc.	Sphingosine pathway modulating compounds for the treatment of cancers
EP3849965A1 (en)	2018-09-12	2021-07-21	Pharmazell GmbH	A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile
AR116479A1 (es) *	2018-09-25	2021-05-12	Quim Sintetica S A	Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
MX2021006692A (es)	2018-12-07	2021-07-07	Synthon Bv	Proceso mejorado para preparar ozanimod.
JP2022528001A (ja) *	2019-03-29	2022-06-07	レセプトス・リミテッド・ライアビリティ・カンパニー	スフィンゴシン１リン酸受容体調節因子
EP3947364A4 (en) *	2019-03-29	2022-12-28	Receptos Llc	SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS
US20220144788A1 (en) *	2019-03-29	2022-05-12	Receptos Llc	Sphingosine 1 phosphate receptor modulators
US20220227722A1 (en) *	2019-04-26	2022-07-21	Receptos Llc	Sphingosine 1 phosphate receptor modulator
CN112062785B (zh) *	2019-06-11	2023-06-27	广东东阳光药业有限公司	奥扎莫德及其中间体的制备方法
MX2022000651A (es)	2019-07-16	2022-03-11	Synthon Bv	Proceso mejorado para preparar ozanimod.
AU2020372647A1 (en)	2019-10-31	2022-06-16	Idorsia Pharmaceuticals Ltd	Combination of a CXCR7 antagonist with an S1P1 receptor modulator
BR112022012846A2 (pt) *	2020-01-06	2022-09-06	Arena Pharm Inc	Métodos de tratamento de condições relacionadas ao receptor s1p1
WO2021175223A1 (zh) *	2020-03-04	2021-09-10	南京明德新药研发有限公司	苯并2-氮杂螺[4.4]壬烷类化合物及其应用
CN115210223A (zh) *	2020-03-04	2022-10-18	南昌弘益药业有限公司	三环类化合物及其应用
AU2021237254A1 (en) *	2020-03-17	2022-10-20	Enzo Biochem, Inc.	Sphingosine pathway modulating compounds for the treatment of coronavirus infection
US20230183194A1 (en)	2020-04-02	2023-06-15	Synthon B.V.	Crystalline form of ozanimod hydrochloride
CN111620788B (zh) *	2020-04-20	2022-09-30	广东莱佛士制药技术有限公司	一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法
EP4321507A1 (en) *	2021-04-09	2024-02-14	Helioeast Pharmaceutical Co., Ltd.	Oxadiazole-substituted spirocyclic compound and application thereof
EP4212156A1 (en)	2022-01-13	2023-07-19	Abivax	Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2023152767A1 (en)	2022-02-11	2023-08-17	Mylan Laboratories Limited	Polymorphic forms of ozanimod hydrochloride
WO2024246174A1 (en)	2023-05-31	2024-12-05	Química Sintética, S.A.	Amorphous and crystalline form of ozanimod hydrochloride

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1479544A (en)	1974-02-07	1977-07-13	American Cyanamid Co	1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
FR2628103B1 (fr)	1988-03-03	1991-06-14	Roussel Uclaf	Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides
US5039802A (en)	1990-04-18	1991-08-13	Merck & Co., Inc.	Arylation process for preparation of chiral catalysts for ketone reduction
AU1886892A (en)	1991-04-12	1992-11-17	Schering Corporation	Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
GB2290790A (en)	1994-06-30	1996-01-10	Merck & Co Inc	Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
ID25477A (id) *	1998-01-23	2000-10-05	Sankyo Co	Turunan-turunan spiropiperidin
AR035585A1 (es) †	2000-09-15	2004-06-16	Pharmacia Corp	Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos
US20040058894A1 (en)	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
EP1581509B1 (en)	2002-12-20	2011-01-19	Merck Sharp & Dohme Corp.	1-(amino)indanes as edg receptor agonists
JP4851933B2 (ja)	2003-04-11	2012-01-11	ピーティーシーセラピューティクス，インコーポレーテッド	１，２，４−オキサジアゾール安息香酸化合物ならびにナンセンス抑制及び疾患の治療のためのその使用
WO2005032465A2 (en)	2003-10-01	2005-04-14	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7605171B2 (en) *	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
US7585881B2 (en)	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20060173183A1 (en)	2004-12-31	2006-08-03	Alantos Pharmaceuticals, Inc.,	Multicyclic bis-amide MMP inhibitors
EP1851188A1 (en)	2005-02-22	2007-11-07	Teva Pharmaceutical Industries Limited	Improved process for the synthesis of enantiomeric indanylamine derivatives
KR100667075B1 (ko)	2005-07-22	2007-01-10	삼성에스디아이 주식회사	주사 구동부 및 이를 포함하는 유기 전계발광 표시장치
RU2420279C3 (ru) †	2005-08-03	2017-03-14	Новартис Аг	Применение ингибиторов hdac для лечения миеломы
WO2007033002A1 (en)	2005-09-14	2007-03-22	Amgen Inc.	Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
PE20070705A1 (es) *	2005-11-25	2007-08-23	Basf Ag	Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales
EP1963509A4 (en)	2005-12-21	2009-07-29	Joseph Gabriele	CATECHOLAMINE-REGULATED PROTEIN
JP2009539762A (ja)	2006-03-13	2009-11-19	ファイザー・プロダクツ・インク	Ｈ３受容体のテトラリン拮抗薬
US20080009534A1 (en) *	2006-07-07	2008-01-10	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
CA2662673A1 (en) *	2006-09-21	2008-03-27	Martin Bolli	Phenyl derivatives and their use as immunomodulators
CA2669104A1 (en)	2006-11-21	2008-05-29	University Of Virginia Patent Foundation	Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
JP2010513283A (ja)	2006-12-15	2010-04-30	アボット・ラボラトリーズ	新規なオキサジアゾール化合物
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
WO2008106224A1 (en)	2007-02-28	2008-09-04	Rib-X Pharmaceuticals, Inc.	Macrolide compounds and methods of making and using the same
GB0725104D0 (en)	2007-12-21	2008-01-30	Glaxo Group Ltd	Compounds
WO2009131090A1 (ja)	2008-04-21	2009-10-29	旭化成ファーマ株式会社	アミノ酸化合物
WO2009151529A1 (en)	2008-05-14	2009-12-17	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors
CN102066752B (zh) *	2008-06-13	2014-02-19	(学)斗源学院	具有回转阀的往复式压缩机
GB0910674D0 (en)	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
WO2011005290A1 (en)	2009-06-23	2011-01-13	Arena Pharmaceuticals, Inc.	Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
GB0911130D0 (en)	2009-06-26	2009-08-12	Glaxo Group Ltd	Novel compounds
EA025672B1 (ru)	2009-11-13	2017-01-30	Рецептос Ллк	Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата
MY160907A (en) *	2009-11-13	2017-03-31	Receptos Inc	Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
PH12012500939A1 (en)	2009-11-13	2016-06-15	Receptos Llc	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
EP2706999B1 (en)	2011-05-13	2019-08-28	Celgene International II Sàrl	Selective heterocyclic sphingosine 1 phosphate receptor modulators
CN106344576A (zh)	2011-10-12	2017-01-25	泰华制药工业有限公司	以拉喹莫德和芬戈莫德的组合治疗多发性硬化症

2010
- 2010-11-15 PH PH1/2012/500939A patent/PH12012500939A1/en unknown
- 2010-11-15 EP EP10830880.0A patent/EP2498610B2/en active Active
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/ja active Active
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 ES ES18160667T patent/ES2858337T3/es active Active
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/pt active IP Right Grant
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 EA EA201690391A patent/EA035768B1/ru not_active IP Right Cessation
- 2010-11-15 ES ES10830880T patent/ES2673160T5/es active Active
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/hu unknown
- 2010-11-15 DK DK10830880.0T patent/DK2498610T4/da active
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/lt unknown
- 2010-11-15 PL PL18160667T patent/PL3406142T3/pl unknown
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/ko active IP Right Grant
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/zh active Active
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en active Application Filing
- 2010-11-15 SM SM20180288T patent/SMT201800288T1/it unknown
- 2010-11-15 PT PT181606674T patent/PT3406142T/pt unknown
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 EA EA201290323A patent/EA024801B1/ru not_active IP Right Cessation
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/pt active IP Right Grant
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/zh active Active
- 2010-11-15 SI SI201031704T patent/SI2498610T2/sl unknown
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
- 2010-11-15 SI SI201032063T patent/SI3406142T1/sl unknown
- 2010-11-15 RS RS20210360A patent/RS61829B1/sr unknown
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/es active IP Right Grant
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/ko active IP Right Grant
- 2010-11-15 RS RS20180647A patent/RS57253B2/sr unknown
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/da active
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/lt unknown
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/tr unknown
- 2010-11-15 PT PT108308800T patent/PT2498610T/pt unknown
- 2010-11-15 SM SM20210169T patent/SMT202100169T1/it unknown
- 2010-11-15 HR HRP20180874TT patent/HRP20180874T4/hr unknown
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/hu unknown
- 2010-11-15 PL PL10830880.0T patent/PL2498610T5/pl unknown
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-03-14 HK HK13103206.9A patent/HK1175948A1/xx unknown
- 2013-03-14 HK HK16100726.3A patent/HK1213874A1/zh unknown
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/ja active Active
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/ja active Pending
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708B1/en unknown
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
2018
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/el unknown
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
2020
- 2020-11-18 LU LU00184C patent/LUC00184I2/en unknown
- 2020-11-18 NO NO2020039C patent/NO2020039I1/no unknown
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/lt unknown
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/fr active Active
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/hu unknown
- 2020-11-19 CY CY2020035C patent/CY2020035I1/el unknown
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/hr unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/el unknown
2024
- 2024-02-29 FI FIEP10830880.0T patent/FI2498610T4/fi active

Also Published As

Publication number	Publication date
EP3868377A1 (en)	2021-08-25
CN105061350A (zh)	2015-11-18
NO2498610T3 (sr)	2018-08-11
MY161854A (en)	2017-05-15
CN105061350B (zh)	2018-05-29
EP2498610A4 (en)	2013-05-22
JP5982705B2 (ja)	2016-08-31
LTPA2020533I1 (lt)	2020-12-10
IL219691B (en)	2019-07-31
SG10201407357PA (en)	2014-12-30
MX2012005560A (es)	2012-10-05
LT2498610T (lt)	2018-06-11
US20170320839A1 (en)	2017-11-09
KR20160149317A (ko)	2016-12-27
IL267956B (en)	2021-01-31
PT2498610T (pt)	2018-06-19
BR122018077504B1 (pt)	2021-05-11
US20110172202A1 (en)	2011-07-14
DK3406142T3 (da)	2021-03-22
PH12015502708A1 (en)	2016-10-17
FR20C1059I1 (sr)	2020-12-25
RS61829B1 (sr)	2021-06-30
LT3406142T (lt)	2021-06-10
CY2020035I2 (el)	2021-03-12
IL219691A0 (en)	2012-07-31
EA201690391A1 (ru)	2016-08-31
FI2498610T4 (fi)	2024-08-29
EA201290323A1 (ru)	2013-05-30
AU2010319983B2 (en)	2015-03-12
EA035768B1 (ru)	2020-08-07
WO2011060392A1 (en)	2011-05-19
IL267956A (en)	2019-09-26
EP3406142B1 (en)	2020-12-23
ES2673160T5 (es)	2024-11-19
SI3406142T1 (sl)	2021-08-31
DK2498610T4 (da)	2024-09-09
HK1213874A1 (zh)	2016-07-15
AU2010319983A2 (en)	2013-09-12
HRP20210446T1 (hr)	2021-05-14
EP2498610B2 (en)	2024-06-19
BR112012011427B8 (pt)	2021-05-25
PH12012500939A1 (en)	2016-06-15
EA024801B1 (ru)	2016-10-31
EP2498610A1 (en)	2012-09-19
HK1175948A1 (en)	2013-07-19
PT3406142T (pt)	2021-03-26
HUE037535T2 (hu)	2018-09-28
CN102762100A (zh)	2012-10-31
CA2986521C (en)	2020-06-30
CY1120338T1 (el)	2019-07-10
PH12015502708B1 (en)	2018-06-06
KR101752124B1 (ko)	2017-06-28
JP5650233B2 (ja)	2015-01-07
FR20C1059I2 (fr)	2021-12-10
US8362048B2 (en)	2013-01-29
JP2015038145A (ja)	2015-02-26
DK2498610T3 (en)	2018-06-14
SI2498610T1 (en)	2018-07-31
KR101721716B1 (ko)	2017-04-10
KR20120102704A (ko)	2012-09-18
ES2858337T3 (es)	2021-09-30
US10239846B2 (en)	2019-03-26
HUS2000045I1 (hu)	2020-12-28
CN102762100B (zh)	2015-07-01
US20130231326A1 (en)	2013-09-05
US20150299149A1 (en)	2015-10-22
BR112012011427B1 (pt)	2021-04-20
JP2014122208A (ja)	2014-07-03
BR112012011427A2 (pt)	2015-10-06
SMT201800288T1 (it)	2018-07-17
LUC00184I2 (sr)	2024-07-01
MY189750A (en)	2022-03-02
CY1124121T1 (el)	2022-05-27
ES2673160T3 (es)	2018-06-20
SI2498610T2 (sl)	2024-10-30
EP2498610B1 (en)	2018-03-14
CA2986521A1 (en)	2011-05-19
HUE054000T2 (hu)	2021-08-30
NZ599915A (en)	2014-07-25
NO2020039I1 (no)	2020-11-18
JP2013510885A (ja)	2013-03-28
EP3406142B8 (en)	2021-03-03
EP3406142A1 (en)	2018-11-28
HRP20180874T1 (hr)	2018-07-13
AU2010319983A1 (en)	2012-05-31
PL2498610T3 (pl)	2018-08-31
CY2020035I1 (el)	2021-03-12
LTC2498610I2 (lt)	2022-06-10
SMT202100169T1 (it)	2021-07-12
RS57253B1 (sr)	2018-08-31
PL2498610T5 (pl)	2024-11-04
TR201807912T4 (tr)	2018-06-21
US9388147B2 (en)	2016-07-12
CA2780772A1 (en)	2011-05-19
PL3406142T3 (pl)	2021-08-30
CA2780772C (en)	2018-01-16
HRP20180874T4 (hr)	2024-09-27
BR122018077504B8 (pt)	2021-05-25

Publication	Publication Date	Title
HUS2000045I1 (hu)	2020-12-28	Szelektív szfingozin-1-foszfát receptor modulátorok és királis szintézis eljárások
IL219690A0 (en)	2012-07-31	Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
HUS2000038I1 (hu)	2020-10-28	Szfingozin foszfát receptor új modulátorai
HK1213873A1 (zh)	2016-07-15	選擇性的雜環 -磷酸鞘氨醇受體調節劑
IL226244A (en)	2014-12-31	Methods for the synthesis of amine thiazolopyridine-2-ylaoxy-phenyl and thiazolopyrazine-2-ylaoxy-phenyl
IL209306A0 (en)	2011-01-31	Novel modulators of sphingosine phosphate receptors